Pulmonary arterial hypertension (PAH) is a devastating disease that involves pulmonary
vasoconstriction, small vessel obliteration, large vessel thickening and obstruction, and …

This review summarizes an expanding body of knowledge indicating that failure to resolve
inflammation and altered immune processes underlie the development of pulmonary arterial …

Heterozygous germ-line mutations in the bone morphogenetic protein type-II receptor
(BMPR-II) gene underlie heritable pulmonary arterial hypertension (HPAH). Although …

Pulmonary arterial hypertension (PAH) describes a group of conditions with a common
hemodynamic phenotype of increased pulmonary artery pressure, driven by progressive …

Background—We previously reported high-throughput RNA sequencing analyses that
identified heightened expression of the chromatin architectural factor High Mobility Group AT …

Pulmonary arterial hypertension (PAH) is characterized by a progressive accumulation of
pulmonary artery smooth muscle cells (PA-SMCs) in pulmonary arterioles leading to the …

Pulmonary arterial hypertension (PAH) remains a mysterious killer that, like cancer, is
characterized by tremendous complexity. PAH development occurs under sustained and …

Mitochondrial dysfunction, inflammation, and mutant bone morphogenetic protein receptor 2
(BMPR2) are associated with pulmonary arterial hypertension (PAH), an incurable disease …

Inflammation is a well‐known feature of heart failure. Studies have shown that while some
inflammation is required for repair during injury and is protective, prolonged inflammation …

This review seeks to provide an update of preclinical findings and available clinical data on
the chronic persistent inflammation and its direct role on the pulmonary arterial hypertension …